Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Non-Current Assets: 2022-2024

Historic Non-Current Assets for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to $40.4 million.

  • Centessa Pharmaceuticals' Non-Current Assets rose 240.08% to $140.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.6 million, marking a year-over-year increase of 240.08%. This contributed to the annual value of $40.4 million for FY2024, which is 10.55% down from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Non-Current Assets stood at $40.4 million for FY2024, which was down 10.55% from $45.2 million recorded in FY2023.
  • In the past 5 years, Centessa Pharmaceuticals' Non-Current Assets ranged from a high of $45.2 million in FY2023 and a low of $6.6 million during FY2022.
  • For the 3-year period, Centessa Pharmaceuticals' Non-Current Assets averaged around $30.7 million, with its median value being $40.4 million (2024).
  • In the last 5 years, Centessa Pharmaceuticals' Non-Current Assets soared by 588.32% in 2023 and then decreased by 10.55% in 2024.
  • Centessa Pharmaceuticals' Non-Current Assets (Yearly) stood at $6.6 million in 2022, then soared by 588.32% to $45.2 million in 2023, then declined by 10.55% to $40.4 million in 2024.